{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:15:52Z","timestamp":1784632552582,"version":"3.55.0"},"reference-count":153,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008725","name":"Maj Institute of Pharmacology Polish Academy of Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Rationale<\/jats:title>\n                <jats:p>The pharmacological effects of antidepressants in modulating noradrenergic transmission as compared to serotonergic transmission in a rat model of Parkinson\u2019s disease under chronic L-DOPA therapy are insufficiently explored.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>The aim of the present study was to investigate the effect of the tricyclic antidepressant desipramine administered chronically alone or jointly with L-DOPA, on motor behavior and monoamine metabolism in selected brain structures of rats with the unilateral 6-OHDA lesion.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The antiparkinsonian activities of L-DOPA and desipramine were assessed behaviorally using a rotation test and biochemically based on changes in the tissue concentrations of noradrenaline, dopamine and serotonin and their metabolites, evaluated separately for the ipsi- and contralateral motor (striatum, substantia nigra) and limbic (prefrontal cortex, hippocampus) structures of rat brain by HPLC method.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Desipramine administered alone did not induce rotational behavior, but in combination with L-DOPA, it increased the number of contralateral rotations more strongly than L-DOPA alone. Both L-DOPA and desipramine\u2009+\u2009L-DOPA significantly increased DA levels in the ipsilateral striatum, substantia nigra, prefrontal cortex and the ipsi- and contralateral hippocampus. The combined treatment also significantly increased noradrenaline content in the ipsi- and contralateral striatum, while L-DOPA alone decreased serotonin level on both sides of the hippocampus.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The performed analysis of the level of monoamines and their metabolites in the selected brain structures suggests that co-modulation of noradrenergic and dopaminergic transmission in Parkinson\u2019s disease by the combined therapy with desipramine\u2009+\u2009L-DOPA may have some positive implications for motor and psychiatric functions but further research is needed to exclude potential negative effects.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00213-022-06238-x","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T07:02:57Z","timestamp":1664521377000},"page":"3633-3656","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Behavioral and neurochemical interactions of the tricyclic antidepressant drug desipramine with L-DOPA in 6-OHDA-lesioned rats. Implications for motor and psychiatric functions in Parkinson\u2019s disease"],"prefix":"10.1007","volume":"239","author":[{"given":"Kinga","family":"Kami\u0144ska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Lenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Konieczny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u017cbieta","family":"Lorenc-Koci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,30]]},"reference":[{"issue":"2","key":"6238_CR1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/0006-8993(94)91511-3","volume":"667","author":"R Arai","year":"1994","unstructured":"Arai R, Karasawa N, Geffard M, Nagatsu T, Nagatsu I (1994) Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenous L-DOPAin the rat, with reference to the involvement of aromatic L-amino acid decarboxylase. Brain Res 667(2):295\u2013299. https:\/\/doi.org\/10.1016\/0006-8993(94)91511-3","journal-title":"Brain Res"},{"issue":"3","key":"6238_CR2","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/0304-3940(95)11817-g","volume":"195","author":"R Arai","year":"1995","unstructured":"Arai R, Karasawa N, Geffard M, Nagatsu I (1995) L-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study. Neurosci Lett 195(3):195\u2013198. https:\/\/doi.org\/10.1016\/0304-3940(95)11817-g","journal-title":"Neurosci Lett"},{"issue":"8","key":"6238_CR3","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/syn.20535","volume":"62","author":"A Arai","year":"2008","unstructured":"Arai A, Tomiyama M, Kannari K et al (2008) Reuptake of L-DOPA-derived extracellular DA in the striatum of a rodent model of Parkinson\u2019s disease via norepinephrine transporter. Synapse 62(8):632\u2013635. https:\/\/doi.org\/10.1002\/syn.20535","journal-title":"Synapse"},{"key":"6238_CR4","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/S00702-005-0402-5","volume":"113","author":"T Archer","year":"2006","unstructured":"Archer T, Fredriksson A (2006) Influence of noradrenaline denervation on MPTP-induced deficits in mice. J Neural Transm 113:1119\u20131129. https:\/\/doi.org\/10.1007\/S00702-005-0402-5","journal-title":"J Neural Transm"},{"key":"6238_CR5","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/J.PBB.2011.09.009","volume":"100","author":"CJ Barnum","year":"2012","unstructured":"Barnum CJ, Bhide N, Lindenbach D et al (2012) Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by \u03b1- and \u03b2-adrenergic receptor antagonists in hemiparkinsonian rats. Pharmacol Biochem Behav 100:607. https:\/\/doi.org\/10.1016\/J.PBB.2011.09.009","journal-title":"Pharmacol Biochem Behav"},{"key":"6238_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/J.1468-1331.2010.03325.X","volume":"18","author":"P Barone","year":"2011","unstructured":"Barone P (2011) Treatment of depressive symptoms in Parkinson\u2019s disease. Eur J Neurol 18:11\u201315. https:\/\/doi.org\/10.1111\/J.1468-1331.2010.03325.X","journal-title":"Eur J Neurol"},{"key":"6238_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/S00441-017-2649-1","volume":"373","author":"EE Benarroch","year":"2018","unstructured":"Benarroch EE (2018) Locus coeruleus. Cell Tissue Res 373:221\u2013232. https:\/\/doi.org\/10.1007\/S00441-017-2649-1","journal-title":"Cell Tissue Res"},{"key":"6238_CR8","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S0006-3223(03)00676-0","volume":"55","author":"S Benmansour","year":"2004","unstructured":"Benmansour S, Altamirano AV, Jones DJ et al (2004) Regulation of the norepinephrine transporter by chronic administration of antidepressants. Biol Psychiat 55:313\u2013316. https:\/\/doi.org\/10.1016\/S0006-3223(03)00676-0","journal-title":"Biol Psychiat"},{"key":"6238_CR9","doi-asserted-by":"publisher","unstructured":"Berridge CW, Stratford TL, Foote SL, Kelley AE (1997) Distribution of dopamine beta-hydroxylase-like immunoreactive fibers within the shell subregion of the nucleus accumbens. Synapse 27:230\u2013241. https:\/\/doi.org\/10.1002\/(SICI)1098-2396(199711)27:3<230::AID-SYN8>3.0.CO;2-E","DOI":"10.1002\/(SICI)1098-2396(199711)27:3<230::AID-SYN8>3.0.CO;2-E"},{"key":"6238_CR10","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1007\/BF01487648","volume":"39","author":"H Bernheimer","year":"1961","unstructured":"Bernheimer H, Birkmayer W, Hornykiewicz O (1961) Verteilung des 5-Hydroxytryptamins (Serotonin) im Gehirn des Menschen und sein Verhalten bei Patienten mit Parkinson-Syndrom. Klin Wochenschr 39:1056\u20131059. https:\/\/doi.org\/10.1007\/BF01487648","journal-title":"Klin Wochenschr"},{"key":"6238_CR11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/0022-510X(73)90175-5","volume":"20","author":"H Bernheimer","year":"1973","unstructured":"Bernheimer H, Birkmayer W, Hornykiewicz O et al (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20:415\u2013455. https:\/\/doi.org\/10.1016\/0022-510X(73)90175-5","journal-title":"J Neurol Sci"},{"key":"6238_CR12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/J.BRAINRES.2015.11.024","volume":"1641","author":"CW Berridge","year":"2016","unstructured":"Berridge CW, Spencer RC (2016) Differential cognitive actions of norepinephrine a2 and a1 receptor signaling in the prefrontal cortex. Brain Res 1641:189\u2013196. https:\/\/doi.org\/10.1016\/J.BRAINRES.2015.11.024","journal-title":"Brain Res"},{"key":"6238_CR13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/0006-8993(79)90056-8","volume":"165","author":"S Bischoff","year":"1979","unstructured":"Bischoff S, Scatton B, Korf J (1979) Biochemical evidence for a transmitter role of dopamine in the rat hippocamus. Brain Res 165:161\u2013165. https:\/\/doi.org\/10.1016\/0006-8993(79)90056-8","journal-title":"Brain Res"},{"key":"6238_CR14","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1111\/J.1460-9568.2012.08202.X","volume":"36","author":"C Bishop","year":"2012","unstructured":"Bishop C, George JA, Buchta W et al (2012) Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats. Eur J Neurosci 36:2839\u20132848. https:\/\/doi.org\/10.1111\/J.1460-9568.2012.08202.X","journal-title":"Eur J Neurosci"},{"key":"6238_CR15","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1017\/S1461145711000812","volume":"15","author":"A Borgkvist","year":"2012","unstructured":"Borgkvist A, Malml\u00f6f T, Feltmann K et al (2012) Dopamine in the hippocampus is cleared by the norepinephrine transporter. Int J Neuropsychopharmacol 15:531\u2013540. https:\/\/doi.org\/10.1017\/S1461145711000812","journal-title":"Int J Neuropsychopharmacol"},{"key":"6238_CR16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak H, del Tredici K, R\u00fcb U et al (2003) Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging 24:197\u2013211. https:\/\/doi.org\/10.1016\/S0197-4580(02)00065-9","journal-title":"Neurobiol Aging"},{"key":"6238_CR17","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/S00441-004-0956-9","volume":"318","author":"H Braak","year":"2004","unstructured":"Braak H, Ghebremedhin E, R\u00fcb U et al (2004) Stages in the development of Parkinson\u2019s disease-related pathology. Cell Tissue Res 318:121\u2013134. https:\/\/doi.org\/10.1007\/S00441-004-0956-9","journal-title":"Cell Tissue Res"},{"key":"6238_CR18","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/J.TINS.2013.06.003","volume":"36","author":"L Brichta","year":"2013","unstructured":"Brichta L, Greengard P, Flajolet M (2013) Advances in the pharmacological treatment of Parkinson\u2019s disease: targeting neurotransmitter systems. Trends Neurosci 36:543\u2013554. https:\/\/doi.org\/10.1016\/J.TINS.2013.06.003","journal-title":"Trends Neurosci"},{"issue":"1","key":"6238_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.neuroscience.2008.12.026","volume":"159","author":"K Buck","year":"2009","unstructured":"Buck K, Ferger B (2009) Comparison of intrastriatal administration of noradrenaline and l-DOPA on dyskinetic movements: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine-lesioned rats. Neuroscience 159(1):16\u201320. https:\/\/doi.org\/10.1016\/j.neuroscience.2008.12.026","journal-title":"Neuroscience"},{"issue":"2","key":"6238_CR20","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/j.1471-4159.2009.06482.x","volume":"112","author":"K Buck","year":"2010","unstructured":"Buck K, Voehringer P, Ferger B (2010) The alpha(2) adrenoceptor antagonist idazoxan alleviates L-DOPA-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats. J Neurochem 112(2):444\u2013452. https:\/\/doi.org\/10.1111\/j.1471-4159.2009.06482.x","journal-title":"J Neurochem"},{"key":"6238_CR21","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1111\/J.1471-4159.1990.TB04599.X","volume":"55","author":"E Carboni","year":"1990","unstructured":"Carboni E, Tanda GL, Frau R, Di Chiara G (1990) Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J Neurochem 55:1067\u20131070. https:\/\/doi.org\/10.1111\/J.1471-4159.1990.TB04599.X","journal-title":"J Neurochem"},{"key":"6238_CR22","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/J.1471-4159.2005.03556.X","volume":"96","author":"E Carboni","year":"2006","unstructured":"Carboni E, Silvagni A, Vacca C, Di Chiara G (2006) Cumulative effect of norepinephrine and dopamine carrier blockade on extracellular dopamine increase in the nucleus accumbens shell, bed nucleus of stria terminalis and prefrontal cortex. J Neurochem 96:473\u2013481. https:\/\/doi.org\/10.1111\/J.1471-4159.2005.03556.X","journal-title":"J Neurochem"},{"key":"6238_CR23","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.neuroscience.2011.07.070","volume":"198","author":"M Carta","year":"2011","unstructured":"Carta M, Bezard E (2011) Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia. Neuroscience 198:245\u2013251. https:\/\/doi.org\/10.1016\/j.neuroscience.2011.07.070","journal-title":"Neuroscience"},{"issue":"5\u20136","key":"6238_CR24","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/00008877-200609000-00005","volume":"7","author":"AR Carta","year":"2006","unstructured":"Carta AR, Pinna A, Morelli M (2006) How reliable is the behavioural evaluation of dyskinesia in animal models of Parkinson\u2019s disease? Behav Pharmacol 7(5\u20136):393\u2013402. https:\/\/doi.org\/10.1097\/00008877-200609000-00005","journal-title":"Behav Pharmacol"},{"issue":"Pt 7","key":"6238_CR25","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1093\/brain\/awm082","volume":"130","author":"M Carta","year":"2007","unstructured":"Carta M, Carlsson T, Kirik D, Bj\u00f6rklund A (2007) Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 130(Pt 7):1819\u20131833. https:\/\/doi.org\/10.1093\/brain\/awm082","journal-title":"Brain"},{"issue":"1","key":"6238_CR26","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3390\/IJMS21010294","volume":"21","author":"A Chagraoui","year":"2020","unstructured":"Chagraoui A, Boulain M, Juvin L et al (2020) L-DOPA in parkinson\u2019s disease: looking at the \u201cfalse\u201d neurotransmitters and their meaning. Int J Mol Sci 21(1):294. https:\/\/doi.org\/10.3390\/IJMS21010294","journal-title":"Int J Mol Sci"},{"key":"6238_CR27","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/CNE.902870308","volume":"287","author":"V Chan-Palay","year":"1989","unstructured":"Chan-Palay V, Asan E (1989) Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson\u2019s disease with and without dementia and depression. J Comp Neurol 287:373\u2013392. https:\/\/doi.org\/10.1002\/CNE.902870308","journal-title":"J Comp Neurol"},{"key":"6238_CR28","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S1474-4422(09)70068-7","volume":"8","author":"KR Chaudhuri","year":"2009","unstructured":"Chaudhuri KR, Schapira AH (2009) Non-motor symptoms of Parkinson\u2019s disease: dopaminergic pathophysiology and treatment. Lancet Neurol 8:464\u2013474. https:\/\/doi.org\/10.1016\/S1474-4422(09)70068-7","journal-title":"Lancet Neurol"},{"key":"6238_CR29","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S1474-4422(06)70373-8","volume":"5","author":"KR Chaudhuri","year":"2006","unstructured":"Chaudhuri KR, Healy DG, Schapira AHV (2006) Non-motor symptoms of Parkinson\u2019s disease: diagnosis and management. Lancet Neurol 5:235\u2013245. https:\/\/doi.org\/10.1016\/S1474-4422(06)70373-8","journal-title":"Lancet Neurol"},{"key":"6238_CR30","doi-asserted-by":"publisher","unstructured":"Chotibut T, Apple DM, Jefferis R, Salvatore MF (2012) Dopamine transporter loss in 6-OHDA Parkinson's model is unmet by parallel reduction in dopamine uptake. PloS One 7(12). https:\/\/doi.org\/10.1371\/journal.pone.0052322","DOI":"10.1371\/journal.pone.0052322"},{"issue":"6","key":"6238_CR31","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1124\/mol.114.093302","volume":"86","author":"T Chotibut","year":"2014","unstructured":"Chotibut T, Fields V, Salvatore MF (2014) Norepinephrine transporter inhibition with desipramine exacerbates L-DOPA-induced dyskinesia: role for synaptic dopamine regulation in denervated nigrostriatal terminals. Mol Pharmacol 86(6):675\u2013685. https:\/\/doi.org\/10.1124\/mol.114.093302","journal-title":"Mol Pharmacol"},{"key":"6238_CR32","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1146\/ANNUREV.NEURO.31.060407.125618","volume":"32","author":"L Clark","year":"2009","unstructured":"Clark L, Chamberlain SR, Sahakian BJ (2009) Neurocognitive mechanisms in depression: implications for treatment. Annu Rev Neurosci 32:57\u201374. https:\/\/doi.org\/10.1146\/ANNUREV.NEURO.31.060407.125618","journal-title":"Annu Rev Neurosci"},{"key":"6238_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.NEUROPHARM.2013.09.017","volume":"77","author":"MM Conti","year":"2014","unstructured":"Conti MM, Ostock CY, Lindenbach D et al (2014) Effects of prolonged selective serotonin reuptake inhibition on the development and expression of l-DOPA-induced dyskinesia in hemi-parkinsonian rats. Neuropharmacology 77:1\u20138. https:\/\/doi.org\/10.1016\/J.NEUROPHARM.2013.09.017","journal-title":"Neuropharmacology"},{"key":"6238_CR34","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/J.PBB.2016.01.004","volume":"142","author":"MM Conti","year":"2016","unstructured":"Conti MM, Goldenberg AAA, Kuberka A et al (2016) Effect of tricyclic antidepressants on L-DOPA-induced dyskinesia and motor improvement in hemi-parkinsonian rats. Pharmacol Biochem Behav 142:64\u201371. https:\/\/doi.org\/10.1016\/J.PBB.2016.01.004","journal-title":"Pharmacol Biochem Behav"},{"key":"6238_CR35","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/J.NEUROPHARM.2016.07.025","volume":"110","author":"MM Conti","year":"2016","unstructured":"Conti MM, Meadows SM, Melikhov-Sosin M et al (2016) Monoamine transporter contributions to L-DOPA effects in hemi-parkinsonian rats. Neuropharmacology 110:125\u2013134. https:\/\/doi.org\/10.1016\/J.NEUROPHARM.2016.07.025","journal-title":"Neuropharmacology"},{"key":"6238_CR36","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/J.NEUBIOREV.2018.05.021","volume":"92","author":"MM Conti","year":"2018","unstructured":"Conti MM, Chambers N, Bishop C (2018) A new outlook on cholinergic interneurons in Parkinson\u2019s disease and L-DOPA-induced dyskinesia. Neurosci Biobehav Rev 92:67\u201382. https:\/\/doi.org\/10.1016\/J.NEUBIOREV.2018.05.021","journal-title":"Neurosci Biobehav Rev"},{"key":"6238_CR37","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/J.NEUROBIOLAGING.2016.08.012","volume":"48","author":"M Coradazzi","year":"2016","unstructured":"Coradazzi M, Gulino R, Fieramosca F et al (2016) Selective noradrenaline depletion impairs working memory and hippocampal neurogenesis. Neurobiol Aging 48:93\u2013102. https:\/\/doi.org\/10.1016\/J.NEUROBIOLAGING.2016.08.012","journal-title":"Neurobiol Aging"},{"key":"6238_CR38","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/J.BRAINRES.2013.10.011","volume":"1541","author":"A Czarnecka","year":"2013","unstructured":"Czarnecka A, Lenda T, Domin H et al (2013) Alterations in the expression of nNOS in the substantia nigra and subthalamic nucleus of 6-OHDA-lesioned rats: the effects of chronic treatment with l-DOPA and the nitric oxide donor, molsidomine. Brain Res 1541:92\u2013105. https:\/\/doi.org\/10.1016\/J.BRAINRES.2013.10.011","journal-title":"Brain Res"},{"key":"6238_CR39","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/J.PNEUROBIO.2016.07.002","volume":"151","author":"P De Deurwaerd\u00e8re","year":"2017","unstructured":"De Deurwaerd\u00e8re P, Di Giovanni G, Millan MJ (2017) Expanding the repertoire of L-DOPA\u2019s actions: a comprehensive review of its functional neurochemistry. Prog Neurobiol 151:57\u2013100. https:\/\/doi.org\/10.1016\/J.PNEUROBIO.2016.07.002","journal-title":"Prog Neurobiol"},{"issue":"1","key":"6238_CR40","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.bbr.2007.01.013","volume":"179","author":"A Dekundy","year":"2007","unstructured":"Dekundy A, Lundblad M, Danysz W, Cenci MA (2007) Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res 179(1):76\u201389. https:\/\/doi.org\/10.1016\/j.bbr.2007.01.013","journal-title":"Behav Brain Res"},{"key":"6238_CR41","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/MDS.24921","volume":"27","author":"K Del Tredici","year":"2012","unstructured":"Del Tredici K, Braak H (2012) Lewy pathology and neurodegeneration in premotor Parkinson\u2019s disease. Mov Disord 27:597\u2013607. https:\/\/doi.org\/10.1002\/MDS.24921","journal-title":"Mov Disord"},{"key":"6238_CR42","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1136\/JNNP-2011-301817","volume":"84","author":"K Del Tredici","year":"2013","unstructured":"Del Tredici K, Braak H (2013) Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson\u2019s disease-related dementia. J Neurol Neurosurg Psychiatry 84:774\u2013783. https:\/\/doi.org\/10.1136\/JNNP-2011-301817","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"6238_CR43","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1093\/JNEN\/61.5.413","volume":"61","author":"K Del Tredici","year":"2002","unstructured":"Del Tredici K, R\u00fcb U, De Vos RAI et al (2002) Where does Parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 61:413\u2013426. https:\/\/doi.org\/10.1093\/JNEN\/61.5.413","journal-title":"J Neuropathol Exp Neurol"},{"key":"6238_CR44","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/J.NBD.2011.10.023","volume":"45","author":"C Delaville","year":"2012","unstructured":"Delaville C, Chetrit J, Abdallah K et al (2012) Emerging dysfunctions consequent to combined monoaminergic depletions in parkinsonism. Neurobiol Dis 45:763\u2013773. https:\/\/doi.org\/10.1016\/J.NBD.2011.10.023","journal-title":"Neurobiol Dis"},{"key":"6238_CR45","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/J.NEUROSCIENCE.2011.11.024","volume":"202","author":"C Delaville","year":"2012","unstructured":"Delaville C, Navailles S, Benazzouz A (2012) Effects of noradrenaline and serotonin depletions on the neuronal activity of globus pallidus and substantia nigra pars reticulata in experimental parkinsonism. Neuroscience 202:424\u2013433. https:\/\/doi.org\/10.1016\/J.NEUROSCIENCE.2011.11.024","journal-title":"Neuroscience"},{"key":"6238_CR46","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/J.NBD.2012.05.019","volume":"47","author":"C Delaville","year":"2012","unstructured":"Delaville C, Zapata J, Cardoit L, Benazzouz A (2012) Activation of subthalamic alpha 2 noradrenergic receptors induces motor deficits as a consequence of neuronal burst firing. Neurobiol Dis 47:322\u2013330. https:\/\/doi.org\/10.1016\/J.NBD.2012.05.019","journal-title":"Neurobiol Dis"},{"key":"6238_CR47","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0006-8993(98)00672-6","volume":"806","author":"JM Delfs","year":"1998","unstructured":"Delfs JM, Zhu Y, Druhan JP, Aston-Jones GS (1998) Origin of noradrenergic afferents to the shell subregion of the nucleus accumbens: anterograde and retrograde tract-tracing studies in the rat. Brain Res 806:127\u2013140. https:\/\/doi.org\/10.1016\/S0006-8993(98)00672-6","journal-title":"Brain Res"},{"key":"6238_CR48","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1002\/MDS.21966","volume":"23","author":"D Devos","year":"2008","unstructured":"Devos D, Dujardin K, Poirot I et al (2008) Comparison of desipramine and citalopram treatments for depression in Parkinson\u2019s disease: a double-blind, randomized, placebo-controlled study. Mov Disord 23:850\u2013857. https:\/\/doi.org\/10.1002\/MDS.21966","journal-title":"Mov Disord"},{"key":"6238_CR49","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/NRN3027","volume":"12","author":"SG Disner","year":"2011","unstructured":"Disner SG, Beevers CG, Haigh EAP, Beck AT (2011) Neural mechanisms of the cognitive model of depression. Nat Rev Neurosci 12:467\u2013477. https:\/\/doi.org\/10.1038\/NRN3027","journal-title":"Nat Rev Neurosci"},{"key":"6238_CR50","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1212\/01.WNL.0000247740.47667.03","volume":"68","author":"ER Dorsey","year":"2007","unstructured":"Dorsey ER, Constantinescu R, Thompson JP et al (2007) Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68:384\u2013386. https:\/\/doi.org\/10.1212\/01.WNL.0000247740.47667.03","journal-title":"Neurology"},{"key":"6238_CR51","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1111\/J.1476-5381.2011.01426.X","volume":"164","author":"S Duty","year":"2011","unstructured":"Duty S, Jenner P (2011) Animal models of Parkinson\u2019s disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol 164:1357\u20131391. https:\/\/doi.org\/10.1111\/J.1476-5381.2011.01426.X","journal-title":"Br J Pharmacol"},{"key":"6238_CR52","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S1353-8020(98)00012-1","volume":"4","author":"H Ehringer","year":"1998","unstructured":"Ehringer H, Hornykiewicz O (1998) Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Parkinsonism Relat Disord 4:53\u201357. https:\/\/doi.org\/10.1016\/S1353-8020(98)00012-1","journal-title":"Parkinsonism Relat Disord"},{"key":"6238_CR53","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1002\/MDS.26048","volume":"29","author":"AJ Espay","year":"2014","unstructured":"Espay AJ, Lewitt PA, Kaufmann H (2014) Norepinephrine deficiency in Parkinson\u2019s disease: the case for noradrenergic enhancement. Mov Disord 29:1710\u20131719. https:\/\/doi.org\/10.1002\/MDS.26048","journal-title":"Mov Disord"},{"key":"6238_CR54","doi-asserted-by":"publisher","first-page":"21824","DOI":"10.1073\/PNAS.1012071107","volume":"107","author":"S Fasano","year":"2010","unstructured":"Fasano S, Bezard E, D\u2019Antoni A et al (2010) Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia. Proc Natl Acad Sci USA 107:21824\u201321829. https:\/\/doi.org\/10.1073\/PNAS.1012071107","journal-title":"Proc Natl Acad Sci USA"},{"key":"6238_CR55","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/JNC.13447","volume":"139","author":"DL Feinstein","year":"2016","unstructured":"Feinstein DL, Kalinin S, Braun D (2016) Causes, consequences, and cures for neuroinflammation mediated via the locus coeruleus: noradrenergic signaling system. J Neurochem 139:154\u2013178. https:\/\/doi.org\/10.1111\/JNC.13447","journal-title":"J Neurochem"},{"key":"6238_CR56","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/S00213-005-2181-Y","volume":"180","author":"B Fern\u00e1ndez-Pastor","year":"2005","unstructured":"Fern\u00e1ndez-Pastor B, Mateo Y, G\u00f3mez-Urquijo S, Javier Meana J (2005) Characterization of noradrenaline release in the locus coeruleus of freely moving awake rats by in vivo microdialysis. Psychopharmacology 180:570\u2013579. https:\/\/doi.org\/10.1007\/S00213-005-2181-Y","journal-title":"Psychopharmacology"},{"key":"6238_CR57","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/J.NEUROSCIENCE.2015.04.027","volume":"298","author":"C Fidalgo","year":"2015","unstructured":"Fidalgo C, Ko WKD, Tronci E et al (2015) Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson\u2019s disease. Neuroscience 298:389\u2013396. https:\/\/doi.org\/10.1016\/J.NEUROSCIENCE.2015.04.027","journal-title":"Neuroscience"},{"key":"6238_CR58","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.2174\/092986707781745550","volume":"14","author":"F Fornai","year":"2007","unstructured":"Fornai F, Di Poggio A, Pellegrini A et al (2007) Noradrenaline in Parkinson\u2019s disease: from disease progression to current therapeutics. Curr Med Chem 14:2330\u20132334. https:\/\/doi.org\/10.2174\/092986707781745550","journal-title":"Curr Med Chem"},{"key":"6238_CR59","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/J.EXPNEUROL.2013.03.002","volume":"247","author":"L Frau","year":"2013","unstructured":"Frau L, Morelli M, Simola N (2013) Performance of movement in hemiparkinsonian rats influences the modifications induced by dopamine agonists in striatal efferent dynorphinergic neurons. Exp Neurol 247:663\u2013672. https:\/\/doi.org\/10.1016\/J.EXPNEUROL.2013.03.002","journal-title":"Exp Neurol"},{"key":"6238_CR60","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/CNE.903590211","volume":"359","author":"C Freed","year":"1995","unstructured":"Freed C, Revay R, Vaughan RA et al (1995) Dopamine transporter immunoreactivity in rat brain. J Comp Neurol 359:340\u2013349. https:\/\/doi.org\/10.1002\/CNE.903590211","journal-title":"J Comp Neurol"},{"key":"6238_CR61","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1002\/MDS.21029","volume":"21","author":"A Funkiewiez","year":"2006","unstructured":"Funkiewiez A, Ardouin C, Cools R et al (2006) Effects of Levodopa and subthalamic nucleus stimulation on cognitive and affective functioning in Parkinson\u2019s disease. Mov Disord 21:1656\u20131662. https:\/\/doi.org\/10.1002\/MDS.21029","journal-title":"Mov Disord"},{"key":"6238_CR62","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1037\/A0023165","volume":"125","author":"NJ Gamo","year":"2011","unstructured":"Gamo NJ, Arnsten AFT (2011) Molecular modulation of prefrontal cortex: rational development of treatments for psychiatric disorders. Behav Neurosci 125:282\u2013296. https:\/\/doi.org\/10.1037\/A0023165","journal-title":"Behav Neurosci"},{"key":"6238_CR63","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/0006-8993(94)90512-6","volume":"668","author":"A Gasbarri","year":"1994","unstructured":"Gasbarri A, Verney C, Innocenzi R et al (1994) Mesolimbic dopaminergic neurons innervating the hippocampal formation in the rat: a combined retrograde tracing and immunohistochemical study. Brain Res 668:71\u201379. https:\/\/doi.org\/10.1016\/0006-8993(94)90512-6","journal-title":"Brain Res"},{"key":"6238_CR64","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1046\/J.1471-4159.1995.64062792.X","volume":"64","author":"DR Gehlert","year":"1995","unstructured":"Gehlert DR, Schober DA, Gackenheimer SL (1995) Comparison of (R)-[3H] tomoxetine and (R\/S)-[3H] nisoxetine binding in rat brain. J Neurochem 64:2792\u20132800. https:\/\/doi.org\/10.1046\/J.1471-4159.1995.64062792.X","journal-title":"J Neurochem"},{"key":"6238_CR65","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3389\/FNEUR.2018.00455","volume":"9","author":"N Gigu\u00e8re","year":"2018","unstructured":"Gigu\u00e8re N, Nanni SB, Trudeau LE (2018) On cell loss and selective vulnerability of neuronal populations in Parkinson\u2019s disease. Front Neurol 9:455. https:\/\/doi.org\/10.3389\/FNEUR.2018.00455","journal-title":"Front Neurol"},{"key":"6238_CR66","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/0896-6273(95)90304-6","volume":"14","author":"PS Goldman-Rakic","year":"1995","unstructured":"Goldman-Rakic PS (1995) Cellular basis of working memory. Neuron 14:477\u2013485. https:\/\/doi.org\/10.1016\/0896-6273(95)90304-6","journal-title":"Neuron"},{"key":"6238_CR67","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0165-0173(99)00045-4","volume":"31","author":"PS Goldman-Rakic","year":"2000","unstructured":"Goldman-Rakic PS, Muly EC 3rd, Williams GV (2000) D1 receptors in prefrontal cells and circuits. Brain Res Rev 31:295\u2013301. https:\/\/doi.org\/10.1016\/S0165-0173(99)00045-4","journal-title":"Brain Res Rev"},{"key":"6238_CR68","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1097\/00002826-199310000-00004","volume":"16","author":"B Gomez-Mancilla","year":"1993","unstructured":"Gomez-Mancilla B, Bedard PJ (1993) Effect of nondopaminergic drugs on L-DOPA induced dyskinesia in MPTP-treated monkeys. Clin Neuropharmacol 16:418\u2013427. https:\/\/doi.org\/10.1097\/00002826-199310000-00004","journal-title":"Clin Neuropharmacol"},{"key":"6238_CR69","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1046\/J.1471-4159.1995.65010111.X","volume":"65","author":"PJ Gresch","year":"1995","unstructured":"Gresch PJ, Sved AF, Zigmond MJ, Finlay JM (1995) Local influence of endogenous norepinephrine on extracellular dopamine in rat medial prefrontal cortex. J Neurochem 65:111\u2013116. https:\/\/doi.org\/10.1046\/J.1471-4159.1995.65010111.X","journal-title":"J Neurochem"},{"issue":"2","key":"6238_CR70","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s002109900167","volume":"361","author":"R Grondin","year":"2000","unstructured":"Grondin R, Hadj Tahar A, Doan VD et al (2000) Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 361(2):181\u2013186. https:\/\/doi.org\/10.1007\/s002109900167","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"6238_CR71","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1212\/WNL.50.5.1327","volume":"50","author":"JH Growdon","year":"1998","unstructured":"Growdon JH, Kieburtz K, McDermott MP et al (1998) Levodopa improves motor function without impairing cognition in mild nondemented Parkinson\u2019s disease patients. Neurology 50:1327\u20131331. https:\/\/doi.org\/10.1212\/WNL.50.5.1327","journal-title":"Neurology"},{"key":"6238_CR72","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/0006-8993(90)90733-R","volume":"510","author":"GM Halliday","year":"1990","unstructured":"Halliday GM, Blumbergs PC, Cotton RGH et al (1990) Loss of brainstem serotonin- and substance P-containing neurons in Parkinson\u2019s disease. Brain Res 510:104\u2013107. https:\/\/doi.org\/10.1016\/0006-8993(90)90733-R","journal-title":"Brain Res"},{"key":"6238_CR73","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/ANA.410270405","volume":"27","author":"GM Halliday","year":"1990","unstructured":"Halliday GM, Li YW, Blumbergs PC et al (1990) Neuropathology of immunohistochemically identified brainstem neurons in Parkinson\u2019s disease. Ann Neurol 27:373\u2013385. https:\/\/doi.org\/10.1002\/ANA.410270405","journal-title":"Ann Neurol"},{"key":"6238_CR74","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1006\/EXNR.1998.6819","volume":"151","author":"B Henry","year":"1998","unstructured":"Henry B, Crossman AR, Brotchie JM (1998) Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson\u2019s disease. Exp Neurol 151:334\u2013342. https:\/\/doi.org\/10.1006\/EXNR.1998.6819","journal-title":"Exp Neurol"},{"issue":"5","key":"6238_CR75","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/1531-8257(199909)14:5<744::aid-mds1006>3.0.co;2-7","volume":"14","author":"B Henry","year":"1999","unstructured":"Henry B, Fox SH, Peggs D et al (1999) The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson\u2019s disease. Mov Disord 14(5):744\u2013753. https:\/\/doi.org\/10.1002\/1531-8257(199909)14:5%3c744::aid-mds1006%3e3.0.co;2-7","journal-title":"Mov Disord"},{"key":"6238_CR76","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/B978-0-12-411512-5.00009-9","volume":"68","author":"JG Hensler","year":"2013","unstructured":"Hensler JG, Artigas F, Bortolozzi A et al (2013) Catecholamine\/serotonin interactions. Systems thinking for brain function and disease. Adv Pharmacol 68:167\u2013197. https:\/\/doi.org\/10.1016\/B978-0-12-411512-5.00009-9","journal-title":"Adv Pharmacol"},{"key":"6238_CR77","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/00004850-199403001-00004","volume":"9","author":"J Hyttel","year":"1994","unstructured":"Hyttel J (1994) Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 9:19\u201326. https:\/\/doi.org\/10.1097\/00004850-199403001-00004","journal-title":"Int Clin Psychopharmacol"},{"key":"6238_CR78","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/JNNP.2007.131045","volume":"79","author":"J Jankovic","year":"2008","unstructured":"Jankovic J (2008) Parkinson\u2019s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79:368\u2013376. https:\/\/doi.org\/10.1136\/JNNP.2007.131045","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"6238_CR79","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1016\/J.NEUROBIOLAGING.2014.05.020","volume":"35","author":"KA Jhang","year":"2014","unstructured":"Jhang KA, Lee EO, Kim HS, Chong YH (2014) Norepinephrine provides short-term neuroprotection against A\u03b21-42 by reducing oxidative stress independent of Nrf2 activation. Neurobiol Aging 35:2465\u20132473. https:\/\/doi.org\/10.1016\/J.NEUROBIOLAGING.2014.05.020","journal-title":"Neurobiol Aging"},{"key":"6238_CR80","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/0006-8993(77)90378-X","volume":"127","author":"BE Jones","year":"1977","unstructured":"Jones BE, Moore RY (1977) Ascending projections of the locus coeruleus in the rat. II. Autoradiographic Study Brain Res 127:23\u201353","journal-title":"Autoradiographic Study Brain Res"},{"key":"6238_CR81","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/J.PHAREP.2017.05.016","volume":"69","author":"K Kami\u0144ska","year":"2017","unstructured":"Kami\u0144ska K, Lenda T, Konieczny J et al (2017) Depressive-like neurochemical and behavioral markers of Parkinson\u2019s disease after 6-OHDA administered unilaterally to the rat medial forebrain bundle. Pharmacol Rep 69:985\u2013994. https:\/\/doi.org\/10.1016\/J.PHAREP.2017.05.016","journal-title":"Pharmacol Rep"},{"key":"6238_CR82","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/J.NEUINT.2018.10.004","volume":"121","author":"K Kami\u0144ska","year":"2018","unstructured":"Kami\u0144ska K, Lenda T, Konieczny J et al (2018) Interactions of the tricyclic antidepressant drug amitriptyline with L-DOPA in the striatum and substantia nigra of unilaterally 6-OHDA-lesioned rats. Relevance to motor dysfunction in Parkinson\u2019s disease. Neurochem Int 121:125\u2013139. https:\/\/doi.org\/10.1016\/J.NEUINT.2018.10.004","journal-title":"Neurochem Int"},{"issue":"1\u20132","key":"6238_CR83","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.neulet.2006.03.059","volume":"402","author":"K Kannari","year":"2006","unstructured":"Kannari K, Shen H, Arai A, Tomiyama M, Baba M (2006) Reuptake of L-DOPA derived extracellular dopamine in the striatum with dopaminergic denervation via serotonin transporters. Neurosci Lett 402(1\u20132):62\u201365. https:\/\/doi.org\/10.1016\/j.neulet.2006.03.059","journal-title":"Neurosci Lett"},{"key":"6238_CR84","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/J.JNS.2009.07.026","volume":"287","author":"HJ Kim","year":"2009","unstructured":"Kim HJ, Park SY, Cho YJ et al (2009) Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment. J Neurol Sci 287:200\u2013204. https:\/\/doi.org\/10.1016\/J.JNS.2009.07.026","journal-title":"J Neurol Sci"},{"key":"6238_CR85","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1093\/BRAIN\/AWM239","volume":"131","author":"SJ Kish","year":"2008","unstructured":"Kish SJ, Tong J, Hornykiewicz O et al (2008) Preferential loss of serotonin markers in caudate versus putamen in Parkinson\u2019s disease. Brain 131:120\u2013131. https:\/\/doi.org\/10.1093\/BRAIN\/AWM239","journal-title":"Brain"},{"key":"6238_CR86","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/S00702-017-1837-1","volume":"125","author":"K Lanza","year":"2018","unstructured":"Lanza K, Bishop C (2018) Serotonergic targets for the treatment of l-DOPA-induced dyskinesia. J Neural Transm 125:1203\u20131216. https:\/\/doi.org\/10.1007\/S00702-017-1837-1","journal-title":"J Neural Transm"},{"key":"6238_CR87","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/J.1468-1331.2008.02058.X","volume":"15","author":"MR Lemke","year":"2008","unstructured":"Lemke MR (2008) Depressive symptoms in Parkinson\u2019s disease. Eur J Neurol 15:21\u201325. https:\/\/doi.org\/10.1111\/J.1468-1331.2008.02058.X","journal-title":"Eur J Neurol"},{"issue":"1","key":"6238_CR88","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/2047-9158-1-4","volume":"1","author":"PA LeWitt","year":"2012","unstructured":"LeWitt PA (2012) Norepinephrine: the next therapeutics frontier for Parkinson\u2019s disease. Transl Neurodegener 1(1):4. https:\/\/doi.org\/10.1186\/2047-9158-1-4","journal-title":"Transl Neurodegener"},{"issue":"1","key":"6238_CR89","doi-asserted-by":"publisher","first-page":"e28370","DOI":"10.1371\/JOURNAL.PONE.0028370","volume":"7","author":"J Liggins","year":"2012","unstructured":"Liggins J, Pihl RO, Benkelfat C, Leyton M (2012) The dopamine augmenter l-dopa does not affect positive mood in healthy human volunteers. PLoS One 7(1):e28370. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0028370","journal-title":"PLoS One"},{"issue":"1","key":"6238_CR90","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.bbr.2006.09.019","volume":"177","author":"HS Lindgren","year":"2007","unstructured":"Lindgren HS, Rylander D, Ohlin KE et al (2007) The \u201cmotor complication syndrome\u201d in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration. Behav Brain Res 177(1):150\u2013159. https:\/\/doi.org\/10.1016\/j.bbr.2006.09.019","journal-title":"Behav Brain Res"},{"key":"6238_CR91","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/S0006-3223(99)00126-2","volume":"46","author":"L Linn\u00e9r","year":"1999","unstructured":"Linn\u00e9r L, Arborelius L, Nomikos GG et al (1999) Locus coeruleus neuronal activity and noradrenaline availability in the frontal cortex of rats chronically treated with imipramine: effect of \u03b12- adrenoceptor blockade. Biol Psychiat 46:766\u2013774. https:\/\/doi.org\/10.1016\/S0006-3223(99)00126-2","journal-title":"Biol Psychiat"},{"key":"6238_CR92","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/J.NEUINT.2013.09.021","volume":"63","author":"E Lorenc-Koci","year":"2013","unstructured":"Lorenc-Koci E, Czarnecka A, Lenda T et al (2013) Molsidomine, a nitric oxide donor, modulates rotational behavior and monoamine metabolism in 6-OHDA lesioned rats treated chronically with L-DOPA. Neurochem Int 63:790\u2013804. https:\/\/doi.org\/10.1016\/J.NEUINT.2013.09.021","journal-title":"Neurochem Int"},{"issue":"1","key":"6238_CR93","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1046\/j.0953-816x.2001.01843.x","volume":"15","author":"M Lundblad","year":"2002","unstructured":"Lundblad M, Andersson M, Winkler C et al (2002) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson\u2019s disease. Eur J Neurosci 15(1):120\u2013132. https:\/\/doi.org\/10.1046\/j.0953-816x.2001.01843.x","journal-title":"Eur J Neurosci"},{"key":"6238_CR94","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/J.EXPNEUROL.2005.02.002","volume":"194","author":"M Lundblad","year":"2005","unstructured":"Lundblad M, Usiello A, Carta M et al (2005) Pharmacological validation of a mouse model of L-DOPA-induced dyskinesia. Exp Neurol 194:66\u201375. https:\/\/doi.org\/10.1016\/J.EXPNEUROL.2005.02.002","journal-title":"Exp Neurol"},{"issue":"1\u20132","key":"6238_CR95","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.brainres.2005.04.019","volume":"1046","author":"T Maeda","year":"2005","unstructured":"Maeda T, Nagata K, Yoshida Y, Kannari K (2005) Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered l-DOPA. Brain Res 1046(1\u20132):230\u2013233. https:\/\/doi.org\/10.1016\/j.brainres.2005.04.019","journal-title":"Brain Res"},{"key":"6238_CR96","doi-asserted-by":"publisher","first-page":"3752","DOI":"10.1523\/JNEUROSCI.2420-20.2021","volume":"41","author":"KM Manz","year":"2021","unstructured":"Manz KM, Coleman BC, Grueter CA et al (2021) Noradrenergic signaling disengages feedforward transmission in the nucleus accumbens shell. J Neurosci 41:3752\u20133763. https:\/\/doi.org\/10.1523\/JNEUROSCI.2420-20.2021","journal-title":"J Neurosci"},{"key":"6238_CR97","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/S0006-3223(99)00139-0","volume":"46","author":"ZM Mao","year":"1999","unstructured":"Mao ZM, Arnsten AFT, Li BM (1999) Local infusion of an \u03b1-1 adrenergic agonist into the prefrontal cortex impairs spatial working memory performance in monkeys. Biol Psychiat 46:1259\u20131265. https:\/\/doi.org\/10.1016\/S0006-3223(99)00139-0","journal-title":"Biol Psychiat"},{"key":"6238_CR98","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1136\/JNNP.36.6.925","volume":"36","author":"GG Marsh","year":"1973","unstructured":"Marsh GG, Markham CH (1973) Does levodopa alter depression and psychopathology in Parkinsonism patients? J Neurol Neurosurg Psychiatry 36:925\u2013935. https:\/\/doi.org\/10.1136\/JNNP.36.6.925","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"6238_CR99","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1046\/J.1471-4159.1998.71020790.X","volume":"71","author":"Y Mateo","year":"1998","unstructured":"Mateo Y, Pineda J, Meana JJ (1998) Somatodendritic \u03b12-adrenoceptors in the locus coeruleus are involved in the in vivo modulation of cortical noradrenaline release by the antidepressant desipramine. J Neurochem 71:790\u2013798. https:\/\/doi.org\/10.1046\/J.1471-4159.1998.71020790.X","journal-title":"J Neurochem"},{"key":"6238_CR100","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1038\/SJ.BJP.0704196","volume":"133","author":"Y Mateo","year":"2001","unstructured":"Mateo Y, Fern\u00e1ndez-Pastor B, Meana JJ (2001) Acute and chronic effects of desipramine and clorgyline on \u03b12-adrenoceptors regulating noradrenergic transmission in the rat brain: a dual-probe microdialysis study. Br J Pharmacol 133:1362\u20131370. https:\/\/doi.org\/10.1038\/SJ.BJP.0704196","journal-title":"Br J Pharmacol"},{"key":"6238_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF01253106","volume":"87","author":"F Mennicken","year":"1992","unstructured":"Mennicken F, Savasta M, Peretti-Renucci R, Feuerstein C (1992) Autoradiographic localization of dopamine uptake sites in the rat brain with 3H-GBR 12935. J Neural Transm 87:1\u201314. https:\/\/doi.org\/10.1007\/BF01253106","journal-title":"J Neural Transm"},{"key":"6238_CR102","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3389\/FNCEL.2017.00274","volume":"11","author":"C Miguelez","year":"2017","unstructured":"Miguelez C, Benazzouz A, Ugedo L, De Deurwaerd\u00e8re P (2017) Impairment of serotonergic transmission by the antiparkinsonian drug L-DOPA: mechanisms and clinical implications. Front Cell Neurosci 11:274. https:\/\/doi.org\/10.3389\/FNCEL.2017.00274","journal-title":"Front Cell Neurosci"},{"key":"6238_CR103","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/NRD3628","volume":"11","author":"MJ Millan","year":"2012","unstructured":"Millan MJ, Agid Y, Br\u00fcne M et al (2012) Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discovery 11:141\u2013168. https:\/\/doi.org\/10.1038\/NRD3628","journal-title":"Nat Rev Drug Discovery"},{"key":"6238_CR104","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/CNE.10898","volume":"466","author":"LH Miner","year":"2003","unstructured":"Miner LH, Schroeter S, Blakely RD, Sesack SR (2003) Ultrastructural localization of the norepinephrine transporter in superficial and deep layers of the rat prelimbic prefrontal cortex and its spatial relationship to probable dopamine terminals. J Comp Neurol 466:478\u2013494. https:\/\/doi.org\/10.1002\/CNE.10898","journal-title":"J Comp Neurol"},{"key":"6238_CR105","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1515\/REVNEURO-2016-0068","volume":"28","author":"HS Moghaddam","year":"2017","unstructured":"Moghaddam HS, Zare-Shahabadi A, Rahmani F, Rezaei N (2017) Neurotransmission systems in Parkinson\u2019s disease. Rev Neurosci 28:509\u2013536. https:\/\/doi.org\/10.1515\/REVNEURO-2016-0068","journal-title":"Rev Neurosci"},{"key":"6238_CR106","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1523\/JNEUROSCI.22-02-00389.2002","volume":"22","author":"JA Mor\u00f3n","year":"2002","unstructured":"Mor\u00f3n JA, Brockington A, Wise RA et al (2002) Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci 22:389\u2013395. https:\/\/doi.org\/10.1523\/JNEUROSCI.22-02-00389.2002","journal-title":"J Neurosci"},{"issue":"1","key":"6238_CR107","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/mds.26103","volume":"30","author":"EV Mosharov","year":"2015","unstructured":"Mosharov EV, Borgkvist A, Sulzer D (2015) Presynaptic effects of levodopa and their possible role in dyskinesia. Mov Disord 30(1):45\u201353. https:\/\/doi.org\/10.1002\/mds.26103","journal-title":"Mov Disord"},{"key":"6238_CR108","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3389\/FNANA.2020.00026","volume":"14","author":"A Mu\u00f1oz","year":"2020","unstructured":"Mu\u00f1oz A, Lopez-Lopez A, Labandeira CM, Labandeira-Garcia JL (2020) Interactions between the serotonergic and other neurotransmitter systems in the basal ganglia: role in Parkinson\u2019s disease and adverse effects of L-DOPA. Front Neuroanat 14:26. https:\/\/doi.org\/10.3389\/FNANA.2020.00026","journal-title":"Front Neuroanat"},{"key":"6238_CR109","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/J.NBD.2010.01.012","volume":"38","author":"S Navailles","year":"2010","unstructured":"Navailles S, Bioulac B, Gross C, De Deurwaerd\u00e8re P (2010) Serotonergic neurons mediate ectopic release of dopamine induced by l-DOPA in a rat model of Parkinson\u2019s disease. Neurobiol Dis 38:136\u2013143. https:\/\/doi.org\/10.1016\/J.NBD.2010.01.012","journal-title":"Neurobiol Dis"},{"key":"6238_CR110","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/J.NBD.2010.11.007","volume":"41","author":"S Navailles","year":"2011","unstructured":"Navailles S, Bioulac B, Gross C, De Deurwaerd\u00e8re P (2011) Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson\u2019s disease. Neurobiol Dis 41:585\u2013590. https:\/\/doi.org\/10.1016\/J.NBD.2010.11.007","journal-title":"Neurobiol Dis"},{"issue":"7","key":"6238_CR111","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/cns.12275","volume":"20","author":"S Navailles","year":"2014","unstructured":"Navailles S, Milan L, Khalki H et al (2014) Noradrenergic terminals regulate L-DOPA-derived dopamine extracellular levels in a region-dependent manner in Parkinsonian rats. CNS Neurosci Ther 20(7):671\u2013678. https:\/\/doi.org\/10.1111\/cns.12275","journal-title":"CNS Neurosci Ther"},{"key":"6238_CR112","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/0304-3940(91)90941-L","volume":"123","author":"K Nishi","year":"1991","unstructured":"Nishi K, Kondo T, Narabayashi H (1991) Destruction of norepinephrine terminals in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice reduces locomotor activity induced by l-DOPA. Neurosci Lett 123:244\u2013247. https:\/\/doi.org\/10.1016\/0304-3940(91)90941-L","journal-title":"Neurosci Lett"},{"key":"6238_CR113","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/J.BBR.2014.05.009","volume":"270","author":"CY Ostock","year":"2014","unstructured":"Ostock CY, Lindenbach D, Goldenberg AA et al (2014) Effects of noradrenergic denervation by anti-DBH-saporin on behavioral responsivity to l-DOPA in the hemi-parkinsonian rat. Behav Brain Res 270:75\u201385. https:\/\/doi.org\/10.1016\/J.BBR.2014.05.009","journal-title":"Behav Brain Res"},{"key":"6238_CR114","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.neuropharm.2015.03.008","volume":"95","author":"CY Ostock","year":"2015","unstructured":"Ostock CY, Hallmark J, Palumbo N, Bhide N, Conti M, George JA, Bishop C (2015) Modulation of L-DOPA\u2019s antiparkinsonian and dyskinetic effects by \u03b12-noradrenergic receptors within the locus coeruleus. Neuropharmacology 95:215\u2013225. https:\/\/doi.org\/10.1016\/j.neuropharm.2015.03.008","journal-title":"Neuropharmacology"},{"key":"6238_CR115","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/0006-8993(94)90796-X","volume":"662","author":"SM Papa","year":"1994","unstructured":"Papa SM, Engber TM, Kask AM, Chase TN (1994) Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res 662:69\u201374. https:\/\/doi.org\/10.1016\/0006-8993(94)90796-X","journal-title":"Brain Res"},{"key":"6238_CR116","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3389\/FPHAR.2020.00435","volume":"11","author":"E Paredes-Rodriguez","year":"2020","unstructured":"Paredes-Rodriguez E, Vegas-Suarez S, Morera-Herreras T et al (2020) The noradrenergic system in Parkinson\u2019s disease. Front Pharmacol 11:435. https:\/\/doi.org\/10.3389\/FPHAR.2020.00435","journal-title":"Front Pharmacol"},{"key":"6238_CR117","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1097\/00005072-199111000-00006","volume":"50","author":"W Paulus","year":"1991","unstructured":"Paulus W, Jellinger K (1991) The neuropathologic basis of different clinical subgroups of parkinson\u2019s disease. J Neuropathol Exp Neurol 50:743\u2013755. https:\/\/doi.org\/10.1097\/00005072-199111000-00006","journal-title":"J Neuropathol Exp Neurol"},{"key":"6238_CR118","volume-title":"The rat brain in stereotaxic coordinates","author":"G Paxinos","year":"2007","unstructured":"Paxinos G, Watson C (2007) The rat brain in stereotaxic coordinates, 6th edn. Academic Press, London","edition":"6"},{"key":"6238_CR119","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1007\/S00702-018-1869-1","volume":"125","author":"S Perez-Lloret","year":"2018","unstructured":"Perez-Lloret S, Rascol O (2018) Efficacy and safety of amantadine for the treatment of l-DOPA-induced dyskinesia. J Neural Transm 125:1237\u20131250. https:\/\/doi.org\/10.1007\/S00702-018-1869-1","journal-title":"J Neural Transm"},{"issue":"4","key":"6238_CR120","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/mds.26475","volume":"31","author":"A Pinna","year":"2016","unstructured":"Pinna A, Ko WKD, Costa G et al (2016) Antidyskinetic effect of A2A and 5HT1A\/1B receptor ligands in two animal models of Parkinson\u2019s disease. Mov Disord 31(4):501\u2013511. https:\/\/doi.org\/10.1002\/mds.26475","journal-title":"Mov Disord"},{"key":"6238_CR121","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/SJ.NPP.1301574","volume":"33","author":"C Pittenger","year":"2008","unstructured":"Pittenger C, Duman RS (2008) Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 33:88\u2013109. https:\/\/doi.org\/10.1038\/SJ.NPP.1301574","journal-title":"Neuropsychopharmacology"},{"key":"6238_CR122","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/BF00431791","volume":"87","author":"A P\u0142a\u017anik","year":"1985","unstructured":"P\u0142a\u017anik A, Danysz W, Kostowski W (1985) A stimulatory effect of intraaccumbens injections of noradrenaline on the behavior of rats in the forced swim test. Psychopharmacology 87:119\u2013123. https:\/\/doi.org\/10.1007\/BF00431791","journal-title":"Psychopharmacology"},{"key":"6238_CR123","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1046\/J.1471-4159.1994.63010195.X","volume":"63","author":"L Pozzi","year":"1994","unstructured":"Pozzi L, Invernizzi R, Cervo L et al (1994) Evidence that extracellular concentrations of dopamine are regulated by noradrenergic neurons in the frontal cortex of rats. J Neurochem 63:195\u2013200. https:\/\/doi.org\/10.1046\/J.1471-4159.1994.63010195.X","journal-title":"J Neurochem"},{"key":"6238_CR124","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1101\/LM.298006","volume":"13","author":"BP Ramos","year":"2006","unstructured":"Ramos BP, Stark D, Verduzco L et al (2006) \u03b12A-adrenoceptor stimulation improves prefrontal cortical regulation of behavior through inhibition of cAMP signaling in aging animals. Learn Mem 13:770\u2013776. https:\/\/doi.org\/10.1101\/LM.298006","journal-title":"Learn Mem"},{"issue":"4","key":"6238_CR125","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/mds.1143","volume":"16","author":"O Rascol","year":"2001","unstructured":"Rascol O, Arnulf I, Peyro-Saint Paul H et al (2001) Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson\u2019s disease. Mov Disord 16(4):708\u2013713. https:\/\/doi.org\/10.1002\/mds.1143","journal-title":"Mov Disord"},{"issue":"9","key":"6238_CR126","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.1523\/JNEUROSCI.09-09-03326.1989","volume":"9","author":"GS Robertson","year":"1989","unstructured":"Robertson GS, Robertson HA (1989) Evidence that L-dopa-induced rotational behavior is dependent on both striatal and nigral mechanisms. J Neurosci 9(9):3326\u20133331. https:\/\/doi.org\/10.1523\/JNEUROSCI.09-09-03326.1989","journal-title":"J Neurosci"},{"issue":"2","key":"6238_CR127","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.bcp.2007.01.036","volume":"74","author":"KS Rommelfanger","year":"2007","unstructured":"Rommelfanger KS, Weinshenker D (2007) Norepinephrine: the redheaded stepchild of Parkinson\u2019s disease. Biochem Pharmacol 74(2):177\u2013190. https:\/\/doi.org\/10.1016\/j.bcp.2007.01.036","journal-title":"Biochem Pharmacol"},{"key":"6238_CR128","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/0006-8993(83)90993-9","volume":"275","author":"B Scatton","year":"1983","unstructured":"Scatton B, Javoy-Agid F, Rouquier L et al (1983) Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson\u2019s disease. Brain Res 275:321\u2013328. https:\/\/doi.org\/10.1016\/0006-8993(83)90993-9","journal-title":"Brain Res"},{"key":"6238_CR129","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/(SICI)1096-9861(20000501)420:2<211::AID-CNE5>3.0.CO;2-3","volume":"420","author":"S Schroeter","year":"2000","unstructured":"Schroeter S, Apparsundaram S, Wiley RG et al (2000) Immunolocalization of the cocaine- and antidepressant-sensitive 1-norepinephrine transporter. J Comp Neurol 420:211\u2013232","journal-title":"J Comp Neurol"},{"key":"6238_CR130","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0301-0082(96)00040-8","volume":"50","author":"RKW Schwarting","year":"1996","unstructured":"Schwarting RKW, Huston JP (1996) The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol 50:275\u2013331. https:\/\/doi.org\/10.1016\/S0301-0082(96)00040-8","journal-title":"Prog Neurobiol"},{"key":"6238_CR131","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/MDS.23884","volume":"26","author":"K Seppi","year":"2011","unstructured":"Seppi K, Weintraub D, Coelho M et al (2011) The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson\u2019s disease. Mov Disord 26:42\u201380. https:\/\/doi.org\/10.1002\/MDS.23884","journal-title":"Mov Disord"},{"key":"6238_CR132","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1523\/JNEUROSCI.18-07-02697.1998","volume":"18","author":"SR Sesack","year":"1998","unstructured":"Sesack SR, Hawrylak VA, Matus C et al (1998) Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. J Neurosci 18:2697\u20132708. https:\/\/doi.org\/10.1523\/JNEUROSCI.18-07-02697.1998","journal-title":"J Neurosci"},{"key":"6238_CR133","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/J.EXPNEUROL.2014.04.011","volume":"257","author":"E Shin","year":"2014","unstructured":"Shin E, Rogers JT, Devoto P et al (2014) Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson\u2019s disease. Exp Neurol 257:25\u201338. https:\/\/doi.org\/10.1016\/J.EXPNEUROL.2014.04.011","journal-title":"Exp Neurol"},{"key":"6238_CR134","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/ana.21472","volume":"64","author":"T Simuni","year":"2008","unstructured":"Simuni T, Sethi K (2008) Nonmotor manifestations of Parkinson\u2019s disease. Ann Neurol 64:65\u201380. https:\/\/doi.org\/10.1002\/ana.21472","journal-title":"Ann Neurol"},{"key":"6238_CR135","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/J.1600-0773.1982.TB00934.X","volume":"50","author":"L Svensson","year":"1982","unstructured":"Svensson L, Ahlenius S (1982) Functional importance of nucleus accumbens noradrenaline in the rat. Acta Pharmacol Toxicol 50:22\u201324. https:\/\/doi.org\/10.1111\/J.1600-0773.1982.TB00934.X","journal-title":"Acta Pharmacol Toxicol"},{"key":"6238_CR136","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/0091-3057(89)90394-8","volume":"33","author":"NR Swerdlow","year":"1989","unstructured":"Swerdlow NR, Koob GF (1989) Norepinephrine stimulates behavioral activation in rats following depletion of nucleus accumbens dopamine. Pharmacol Biochem Behav 33:595\u2013599. https:\/\/doi.org\/10.1016\/0091-3057(89)90394-8","journal-title":"Pharmacol Biochem Behav"},{"key":"6238_CR137","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/NATURE19325","volume":"537","author":"T Takeuchi","year":"2016","unstructured":"Takeuchi T, Duszkiewicz AJ, Sonneborn A et al (2016) Locus coeruleus and dopaminergic consolidation of everyday memory. Nature 537:357\u2013362. https:\/\/doi.org\/10.1038\/NATURE19325","journal-title":"Nature"},{"issue":"3","key":"6238_CR138","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1097\/00001756-199902250-00034","volume":"10","author":"H Tanaka","year":"1999","unstructured":"Tanaka H, Kannari K, Maeda T, Tomiyama M, Suda T, Matsunaga M (1999) Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. NeuroReport 10(3):631\u2013634. https:\/\/doi.org\/10.1097\/00001756-199902250-00034","journal-title":"NeuroReport"},{"key":"6238_CR139","first-page":"427","volume":"260","author":"SM Tejani-Butt","year":"1992","unstructured":"Tejani-Butt SM (1992) [3H]Nisoxetine: a radioligand for quantitation of norepinephrine uptake sites by autoradiography or by homogenate binding. J Pharmacol Exp Ther 260:427\u2013436","journal-title":"J Pharmacol Exp Ther"},{"key":"6238_CR140","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/S00702-017-1825-5","volume":"125","author":"E Tronci","year":"2018","unstructured":"Tronci E, Francardo V (2018) Animal models of l-DOPA-induced dyskinesia: the 6-OHDA-lesioned rat and mouse. J Neural Transm 125:1137\u20131144. https:\/\/doi.org\/10.1007\/S00702-017-1825-5","journal-title":"J Neural Transm"},{"key":"6238_CR141","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/J.1365-201X.1971.TB11000.X","volume":"82","author":"U Ungerstedt","year":"1971","unstructured":"Ungerstedt U (1971) Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand 82:69\u201393. https:\/\/doi.org\/10.1111\/J.1365-201X.1971.TB11000.X","journal-title":"Acta Physiol Scand"},{"key":"6238_CR142","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1093\/AJE\/KWG068","volume":"157","author":"SK Van Den Eeden","year":"2003","unstructured":"Van Den Eeden SK, Tanner CM, Bernstein AL et al (2003) Incidence of Parkinson\u2019s disease: variation by age, gender, and race\/ethnicity. Am J Epidemiol 157:1015\u20131022. https:\/\/doi.org\/10.1093\/AJE\/KWG068","journal-title":"Am J Epidemiol"},{"key":"6238_CR143","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/J.2042-7158.1983.TB02972.X","volume":"35","author":"MA Vance","year":"1983","unstructured":"Vance MA, Blumberg JB (1983) Effect of catecholamines on locomotor activity and cyclic AMP in nucleus accumbens in rats. J Pharm Pharmacol 35:402\u2013404. https:\/\/doi.org\/10.1111\/J.2042-7158.1983.TB02972.X","journal-title":"J Pharm Pharmacol"},{"key":"6238_CR144","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/0306-4522(85)90275-1","volume":"14","author":"C Verney","year":"1985","unstructured":"Verney C, Baulac M, Berger B et al (1985) Morphological evidence for a dopaminergic terminal field in the hippocampal formation of young and adult rat. Neuroscience 14:1039\u20131052. https:\/\/doi.org\/10.1016\/0306-4522(85)90275-1","journal-title":"Neuroscience"},{"key":"6238_CR145","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/NN1846","volume":"10","author":"S Vijayraghavan","year":"2007","unstructured":"Vijayraghavan S, Wang M, Birnbaum SG et al (2007) Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nat Neurosci 10:376\u2013384. https:\/\/doi.org\/10.1038\/NN1846","journal-title":"Nat Neurosci"},{"issue":"12","key":"6238_CR146","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1002\/jnr.23439","volume":"92","author":"Y Wang","year":"2014","unstructured":"Wang Y, Wang HS, Wang T et al (2014) L-DOPA-induced dyskinesia in a rat model of Parkinson\u2019s disease is associated with the fluctuational release of norepinephrine in the sensorimotor striatum. J Neurosci Res 92(12):1733\u20131745. https:\/\/doi.org\/10.1002\/jnr.23439","journal-title":"J Neurosci Res"},{"key":"6238_CR147","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1176\/JNP.2006.18.3.397","volume":"18","author":"K Witt","year":"2006","unstructured":"Witt K, Daniels C, Herzog J et al (2006) Differential effects of L-dopa and subthalamic stimulation on depressive symptoms and hedonic tone in Parkinson\u2019s disease. J Neuropsychiatry Clin Neurosci 18:397\u2013401. https:\/\/doi.org\/10.1176\/JNP.2006.18.3.397","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"6238_CR148","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/J.LFS.2017.08.020","volume":"188","author":"X Xie","year":"2017","unstructured":"Xie X, Chen Y, Wang Q et al (2017) Desipramine rescues age-related phenotypes in depression-like rats induced by chronic mild stress. Life Sci 188:96\u2013100. https:\/\/doi.org\/10.1016\/J.LFS.2017.08.020","journal-title":"Life Sci"},{"key":"6238_CR149","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/J.BRAINRES.2016.01.005","volume":"1641","author":"B Xing","year":"2016","unstructured":"Xing B, Li YC, Gao WJ (2016) Norepinephrine versus dopamine and their interaction in modulating synaptic function in the prefrontal cortex. Brain Res 1641:217\u2013233. https:\/\/doi.org\/10.1016\/J.BRAINRES.2016.01.005","journal-title":"Brain Res"},{"key":"6238_CR150","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1046\/J.1471-4159.1998.71010274.X","volume":"71","author":"BK Yamamoto","year":"1998","unstructured":"Yamamoto BK, Novotney S (1998) Regulation of extracellular dopamine by the norepinephrine transporter. J Neurochem 71:274\u2013280. https:\/\/doi.org\/10.1046\/J.1471-4159.1998.71010274.X","journal-title":"J Neurochem"},{"key":"6238_CR151","doi-asserted-by":"publisher","first-page":"8528","DOI":"10.1523\/JNEUROSCI.17-21-08528.1997","volume":"17","author":"J Zahrt","year":"1997","unstructured":"Zahrt J, Taylor JR, Mathew RG, Arnsten AFT (1997) Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance. J Neurosci 17:8528\u20138535. https:\/\/doi.org\/10.1523\/JNEUROSCI.17-21-08528.1997","journal-title":"J Neurosci"},{"key":"6238_CR152","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1001\/ARCHNEUR.60.3.337","volume":"60","author":"C Zarow","year":"2003","unstructured":"Zarow C, Lyness SA, Mortimer JA, Chui HC (2003) Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 60:337\u2013341. https:\/\/doi.org\/10.1001\/ARCHNEUR.60.3.337","journal-title":"Arch Neurol"},{"key":"6238_CR153","doi-asserted-by":"publisher","first-page":"104549","DOI":"10.1016\/J.NEUINT.2019.104549","volume":"131","author":"MY Zhu","year":"2019","unstructured":"Zhu MY, Raza MU, Zhan Y, Fan Y (2019) Norepinephrine upregulates the expression of tyrosine hydroxylase and protects dopaminegic neurons against 6-hydrodopamine toxicity. Neurochem Int 131:104549. https:\/\/doi.org\/10.1016\/J.NEUINT.2019.104549","journal-title":"Neurochem Int"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-022-06238-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-022-06238-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-022-06238-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T05:09:56Z","timestamp":1666242596000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-022-06238-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":153,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["6238"],"URL":"https:\/\/doi.org\/10.1007\/s00213-022-06238-x","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,30]]},"assertion":[{"value":"3 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}